BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 23288633)

  • 1. Novel antineoplastics targeting genetic changes in colorectal cancer.
    Joudeh J; Allen JE; Das A; Prabhu V; Farbaniec M; Adler J; El-Deiry WS
    Adv Exp Med Biol; 2013; 779():1-34. PubMed ID: 23288633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Treatment of Colorectal Cancer During Pregnancy: Cytotoxic Chemotherapy and Targeted Therapy Challenges.
    Rogers JE; Dasari A; Eng C
    Oncologist; 2016 May; 21(5):563-70. PubMed ID: 27000464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of novel targeted agents in the treatment of metastatic colorectal cancer.
    Berge E; Thompson C; Messersmith W
    Clin Colorectal Cancer; 2011 Dec; 10(4):266-78. PubMed ID: 21903484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting NF-kappaB for colorectal cancer.
    Sakamoto K; Maeda S
    Expert Opin Ther Targets; 2010 Jun; 14(6):593-601. PubMed ID: 20367537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Small Molecules Targeting the Wnt Signaling Pathway in Cancer Stem Cells for the Treatment of Colorectal Cancer.
    Song L; Li Y; He B; Gong Y
    Clin Colorectal Cancer; 2015 Sep; 14(3):133-45. PubMed ID: 25799881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translation initiation in colorectal cancer.
    Parsyan A; Hernández G; Meterissian S
    Cancer Metastasis Rev; 2012 Jun; 31(1-2):387-95. PubMed ID: 22418835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel ent-kaurane diterpenoid executes antitumor function in colorectal cancer cells by inhibiting Wnt/β-catenin signaling.
    Ye Q; Yao G; Zhang M; Guo G; Hu Y; Jiang J; Cheng L; Shi J; Li H; Zhang Y; Liu H
    Carcinogenesis; 2015 Mar; 36(3):318-26. PubMed ID: 25600769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel and Emerging Targeted Therapies of Colorectal Cancer.
    Finnberg N; Gokare P; El-Deiry WS
    Curr Clin Pharmacol; 2015; 10(4):279-98. PubMed ID: 26548905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
    De Mattia E; Cecchin E; Toffoli G
    Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF in metastatic colorectal cancer: the future starts now.
    Orlandi A; Calegari A; Inno A; Berenato R; Caporale M; Niger M; Bossi I; Di Bartolomeo M; de Braud F; Pietrantonio F
    Pharmacogenomics; 2015 Dec; 16(18):2069-81. PubMed ID: 26615988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway.
    Kodach LL; Bleuming SA; Peppelenbosch MP; Hommes DW; van den Brink GR; Hardwick JC
    Gastroenterology; 2007 Oct; 133(4):1272-81. PubMed ID: 17919499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colorectal cancer models for novel drug discovery.
    Golovko D; Kedrin D; Yilmaz ÖH; Roper J
    Expert Opin Drug Discov; 2015; 10(11):1217-29. PubMed ID: 26295972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic role and therapeutic target of leptin signaling in colorectal cancer.
    Zhou W; Tian Y; Gong H; Guo S; Luo C
    Expert Opin Ther Targets; 2014 Aug; 18(8):961-71. PubMed ID: 24946986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the PI3K pathway in colorectal cancer.
    Papadatos-Pastos D; Rabbie R; Ross P; Sarker D
    Crit Rev Oncol Hematol; 2015 Apr; 94(1):18-30. PubMed ID: 25591826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The implications of colorectal cancer molecular biology in clinical practice.
    Kargozaran H; Kahlenberg M; Khatri VP
    Surg Oncol Clin N Am; 2008 Apr; 17(2):341-55, viii-ix. PubMed ID: 18375356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combination of eicosapentaenoic acid-free fatty acid, epigallocatechin-3-gallate and proanthocyanidins has a strong effect on mTOR signaling in colorectal cancer cells.
    D'Angelo L; Piazzi G; Pacilli A; Prossomariti A; Fazio C; Montanaro L; Graziani G; Fogliano V; Munarini A; Bianchi F; Belluzzi A; Bazzoli F; Ricciardiello L
    Carcinogenesis; 2014 Oct; 35(10):2314-20. PubMed ID: 25123131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From Molecular Biology to Clinical Trials: Toward Personalized Colorectal Cancer Therapy.
    Palma S; Zwenger AO; Croce MV; Abba MC; Lacunza E
    Clin Colorectal Cancer; 2016 Jun; 15(2):104-15. PubMed ID: 26777471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On target? Strategies and progress in the development of therapies for colorectal cancer targeted against WNT signalling.
    McDonald SL; Silver AR
    Colorectal Dis; 2011 Apr; 13(4):360-9. PubMed ID: 20015264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New strategies for colorectal cancer prevention and treatment.
    Saha D; Roman C; Beauchamp RD
    World J Surg; 2002 Jul; 26(7):762-6. PubMed ID: 11948369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.